Philip Ferrone, MD, to join Apellis Pharmaceuticals as Chief Medical Retina Advisor
Ferrone’s role will be effective as of March 18, 2024.
(Image credit: AdobeStock/Katsiaryna)
Philip Ferrone, MD, is set to join Apellis Pharmaceuticals Inc. as the company’s Chief Medical Retina Advisor. His title and position will be effective on March 18, 2024.
Ferrone is a retina specialist who serves as the director of clinical research at Vitreoretinal Consultants in New York and will continue in the role following his appointment at Apellis. In addition to his current work, Ferrone previously served as the president of the American Society of Retina Specialists (ASRS) and has been a part of the board of directors for 18 years. He is also a past president of The Foundation of the ASRS, which aims to raise patient awareness and education about retina health.1
In the news release1, Caroline Baumal, MD, Chief Medical Officer, Apellis, shared how “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team. Phil has extensive expertise in retina research and patient care, which will be invaluable as we continue to bring SYFOVRE to patients with GA and advance our retina pipeline.”
His direct work with the company’s pegcetacoplan injection (SYFOVRE) as treatment for geographic atrophy (GA) lends to his work in this role. On the subject of this new role, Ferrone shared his thought in a press release1, saying, “It is an honor to join Apellis in its mission to deliver life-changing treatments for patients living with serious diseases. I was an early adopter of SYFOVRE and have realized first-hand how impactful this treatment is for GA patients. I look forward to working closely with Caroline and this tremendously talented team to advance care for patients with this devastating disease.”
